Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients
Experimental Hematology, 08/17/2012
Jalkanen SE et al. – Suboptimal imatinib response is related to increased phosphorylation of several proteins at diagnosis, which might guide the selection of Tyrosine kinase inhibitors (TKIs) therapy. Furthermore, the activation of additional BCR–ABL–independent pathways in nonresponder patients (such as the anti–apoptotic HSP27 pathway) may reveal novel therapy targets.
